oxazolidin-2-one has been researched along with Metabolic Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alivanis, P; Aperis, G; Paliouras, C; Papakonstantinou, N; Tsampikaki, E | 1 |
| Arsenault, BJ; Brodeur, MR; Rhainds, D; Tardif, JC | 1 |
2 review(s) available for oxazolidin-2-one and Metabolic Syndrome
| Article | Year |
|---|---|
Anacetrapib: a new weapon against dyslipidemia.
Topics: Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Oxazolidinones | 2011 |
An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Oxazolidinones; Plaque, Atherosclerotic; Recurrence; Sulfhydryl Compounds | 2012 |